Different clinical trials, which enrolled patients with advanced NSCLC and a high PD-L1 score (i.e., an immunohistochemical tumor proportion score (TPS) of at least 50%) compared CKI monotherapy with standard chemotherapy, showing a significant increase in progression-free (PFS) and overall survival (OS) in favor of the CKI-treated patient group [7,8,9]. The gene discussed is CD274; the disease is neoplasm.